Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018, Article ID 8576179, 9 pages
https://doi.org/10.1155/2018/8576179
Research Article

Circulating Serum Level of Visfatin in Patients with Endometrial Cancer

1Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
2General Pathology Department, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111 Szczecin, Poland
3Department of Mathematics Applications in Economy, West Pomeranian University of Technology, Al. Piastów 17, 70-310 Szczecin, Poland

Correspondence should be addressed to Aneta Cymbaluk-PÅ‚oska; lp.atad@catena

Received 30 August 2017; Revised 22 October 2017; Accepted 28 November 2017; Published 4 January 2018

Academic Editor: Koichiro Wada

Copyright © 2018 Aneta Cymbaluk-Płoska et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Obesity is a well-known factor that leads to many diseases including endometrial cancer. The adipose tissue is a heterogeneous organ of internal secretion. Visfatin is a newly discovered protein produced by fat tissues. The purpose of this work was to evaluate serum level concentrations of visfatin in patients with endometrial cancer based on clinical progression and histopathological tumor differentiation. The diagnostic capabilities of visfatin protein in high differentiation (FIGO III and IV) from a lower (FIGO I and II) clinical stage and prognostic degree of cell differentiation (G1 versus G2, G2 versus G3) on the basis of the analysis of the area under the ROC curve are as follows: 0.87, 0.81, and 0.86. Significantly higher concentrations of visfatin have been observed in patients with invasion of the blood vessels () and lymph node metastases () in reference to the depth of infiltration of the endometrium (), as well as the size of the tumor (). Visfatin serum concentrations did not differ due to the invasion of the lymphatic vessels only. Visfatin seems to be a good marker of endometrial cancer progress. High visfatin serum level predicts poor prognosis in endometrial cancer patients.